A Phase II Study of AZD2171 [cediranib] in Previously Untreated Patients With Metastatic or Recurrent Malignant Melanoma.
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2018
At a glance
- Drugs Cediranib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 Feb 2016 Results published in the Investigational New Drugs
- 03 Feb 2016 Status changed from completed to discontinued according to results published in the Investigational New Drugs.